Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Laurus Labs Ltd. ( (IN:LAURUSLABS) ) just unveiled an update.
Laurus Labs Ltd. has announced the submission of a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. This submission, facilitated by KFin Technologies Limited, confirms the details of securities dematerialized and rematerialized during the period, ensuring compliance with regulatory requirements. This move underscores Laurus Labs’ commitment to transparency and adherence to regulatory standards, which is crucial for maintaining investor confidence and market integrity.
More about Laurus Labs Ltd.
Laurus Labs Ltd. operates in the pharmaceutical industry, providing a range of products and services primarily focused on the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company is known for its strong presence in the generic drug market and serves a global clientele.
YTD Price Performance: -8.40%
Average Trading Volume: 113,747
Current Market Cap: 303.8B INR
See more insights into LAURUSLABS stock on TipRanks’ Stock Analysis page.